Factor Xa Inhibitor
Andexanet alfa postmarketing trial stopped early due to superior efficacy
AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release.
Factor Xa inhibitor use linked to risk for ILD in patients with atrial fibrillation
In patients with nonvalvular atrial fibrillation receiving oral anticoagulants, factor Xa inhibitors appeared associated with increased risk for interstitial lung disease, according to a study published in JAMA Network Open.
The promise of a specific reversal agent for Factor Xa inhibitors
In recent years, medicine has witnessed the arrival of the direct oral anticoagulants, which include the direct thrombin inhibitor dabigatran and the Factor Xa inhibitors apixaban, edoxaban and rivaroxaban.
Part of the Healio Network
Warfarin
Warfarin is an anticoagulant that acts by inhibiting the enzyme that recycles vitamin K from its oxidized form resulting in active vitamin K depletion.
Part of the Healio Network
Rivaroxaban
Rivaroxaban (Xarelto, Janssen/Bayer) is a direct factor Xa inhibitor used orally in the prevention of thromboembolism in the setting of atrial fibrillation or atrial flutter.